ERBB2 and breast carcinoma: In the Olympia trial, 18.2% of patients receiving adjuvant olaparib had hormone receptor positive, HER2-negative breast cancer at high risk of relapse, defined as patients with residual disease after NAC and a CPS + EG score of 3 or more (in the neoadjuvant group) or 4 positive lymph nodes or more (in the adjuvant group) [13].